In HR+ breast cancer, nuclear receptors, including ER have been shown to directly regulate metabolic reprogramming by affecting the expression of key metabolic genes and indirectly by modulating the expression and activity of oncogenes and oncogenic signaling pathways (Table 1) [19,20,21,59]. This evidence concerns the gene ESR1 and breast carcinoma.